Paxlovid
MPP
KEI Comments on the Pfizer MPP License for PF-07321332 + Ritonavir (sold by Pfizer under the brand name Paxlovid)
On November 16, 2021, Pfizer and the Medicines Patent Pool (MPP) announced at voluntary license to patented inventions and know-how to manufacture a two drug combination to treat COVID-19. The MPP announcement is here and here. Additional comments on the… Continue Reading
KEI Comments on the Medicines Patent Pool/Merck License for Molnupiravir
(For more resources, please see our page on molnupiravir.) The Medicines Patent Pool (MPP) and Merck Sharp & Dohme (“MSD” or “Merck”) have announced a voluntary license for the generic manufacture and sale of molnupiravir. A joint press release from… Continue Reading
KEI statement on GSK’s announcement of policies to expand access to patented medicines
GSK has made a major announcement of new policies to expand access to its patented medicines. A copy of the press statement is here. Continue Reading